Influenza virus-inhibitory effects of a series of germanium- and silicon-centred polyoxometalates

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 2, 1997, Pages 75-83

  Huffman, J H ^a   Sidwell, R W ^a   Barnard, D L ^a   Morrison, A ^a   Otto, M J ^b   Hill, C L ^c   Schinazi, R F ^d  

^a UTAH STATE UNIVERSITY   (United States)

^b Avid Therapeutics Inc   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

animal model; antiviral; heteropolytungstate; in vitro assay; influenza virus; polyoxometalate

Indexed keywords

ANTIVIRUS AGENT; GERMANIUM; METAL; SILICON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; IN VITRO STUDY; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031059163     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800201     Document Type: Article

References (23)

1. Blasecki JW (1994) Of therapy, toxicity and tungstates: the anti-retroviral pharmacology of polyoxometalates. In Polyoxometalates: From Platonic Solids to Anti-Retroviral Activity. Edited by MT Pope and A Muller. Dordrecht: Kluwer Academic, pp. 359-371.
2. Carrano RA, Inliucci JD, Luce JK, Page JA & Imondi AR (1984). MVE-2: development of an immuno-adjuvant for cancer treatment. In Immune Modulation Agents and Their Mechanisms. Edited by RL Fenichel and MA Chirigos. New York: Marcel Dekker, pp. 243-260.
3. 5. Journal of the American Chemical Society 106: 7274-7277.
4. + salt. Inorganic Chemistry 28: 1573-1579.
5. Fukuma M, Seto Y & Yamase T (1991) In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus. Antiviral Research 16: 327-339.
6. Hill CL, Weeks MS & Schinazi RF (1990) Anti-HIV-1 activity, toxicity, and stability studies of representative structural families of polyoxometalates. Journal of Medicinal Chemistry 33: 2767-2772.
7. Hill CL, Kim GS, Prosser-McCartha CM & Judd D (1993) Polyoxometalates in catalytic selective homogeneous oxidation and anti-HIV chemotherapy. Molecular Engineering 3: 263-275.
8. Hill CL, Judd DA, Boudinot FD & Schinazi RF (1995) Polyoxometalates - revisiting a promising class of antiviral agents. International Antiviral News 3: 159-160.
9. Ikeda S, Neyts J, Yamamoto N, Murrer B, Theobald B, Bossard G, Henson G, Abrams M, Picker D & De Clercq E (1993) In vitro activity of a novel series of polyoxosilicotungstates against human myxo-, herpes-and retroviruses. Antiviral Chemistry and Chemotherapy 4: 253-262.
10. Ikeda S, Nishiya S, Yamamoto A, Yamase T, Nishimura C & De Clercq E (1994) Antiviral activity of a Keggin polyoxotungstate PM-19 against herpes simplex virus in mice. Antiviral Chemistry and Chemotherapy 5: 47-50.
11. 2O on human immunodeficiency virus type 1. Antiviral Research 20: 317-331.
12. Judd DA, Hill CL & Schinazi RF (1994) Relationship of the molecular size and charge density of polyoxometalates to their anti-gp120-CD4-binding activity. Antiviral Chemistry and Chemotherapy 5: 410-414.
13. Kim G-S, Judd DA, Hill CL & Schinazi RF (1994) Synthesis, characterization, and biological activity of a new potent class of anti-HIV agents, the peroxoniobium-substituted heteropolytungstates. Journal of Medicinal Chemistry 37: 816-820.
14. McManus NH (1976) Microtiter assay for interferon: microspectrophotometric quantitation of cytopathic effect. Applied Environmental Microbiology 31: 35-38.
15. Moore PS, Jones CJ, Mahmood N, Evans IG, Goff M & Cooper R (1995) Anti-human immunodeficiency virus activity of polyoxotungstates and their inhibition of human immunodeficiency virus reverse transcriptase. Journal of Biochemistry 307: 129-134.
16. Shigeta S, Mori S, Watanabe J, Baba M, Khenkin AM, Hill CL & Schinazi RF (1995) In vitro antimyxovirus and anti-human immunodeficiency virus activities of polyoxometalates. Antiviral Chemistry and Chemotherapy 6: 114-122.
17. Sidwell RW & Huffman JH (1971) Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Applied Microbiology 22: 797-801.
18. Sidwell RW, Huffman JH, Call EW, Alaghamandan H, Cook PD & Robins RK (1985) Activity of selenazofurin against influenza A and B viruses in vitro. Antimicrobial Agents and Chemotherapy 28: 375-377.
19. Sidwell RW, Huffman JH, Gilbert J, Moscon B, Pederson G, Burger R & Warren RP (1992) Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrobial Agents and Chemotherapy 36: 473-476.
20. Sidwell RW, Bailey KW, Wong MH & Huffman JH (1995) In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Chemotherapy 41: 455-461.
21. Sidwell RW, Huffman JH, Bailey KW, Gessaman A, Otto MJ, Hill C & Schinazi RF (1996) In vitro and in vivo influenza-inhibitory effects of a series of polyoxometalates. Antiviral Research 30: A28.
22. Swart PJ & Meijer DKF (1994) Negatively-charged albumins: a novel class of polyanionic proteins with a potent anti-HIV activity. International Antiviral News 2: 69-71.
23. Yamamoto N, Schols D, De Clercq E, Debyser Z, Pauwels R, Balzarini J, Nakashima H, Baba M, Hosoya M, Snoeck R, Neyts J, Andrei G, Murrer BA, Theobald B, Bossard G, Henson G, Abrams M & Picker D (1992) Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. Molecular Pharmacology 42: 1109-1117.